A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

Completed · Phase 1

Conditions studied: Healthy Volunteers, Healthy

In brief

GC4419 is being studied to treat and prevent oral mucositis (painful inflammation) in cancer patients who receive radiation and chemotherapy. In this study, GC4419 will be mixed with a small amount of radioactive material in order to find out how much study drug is in the blood and to see how the drug is processed and eliminated from the body. The safety and how subjects tolerate the study drug will also be studied.

Key facts

Study ID

NCT03163173

Run by

Galera Therapeutics, Inc.

People needed

6

Starts

2017-08-14

Expected to finish

2017-10-13

Last updated by the study team

2017-11-17

Who can join

Age: 19 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy, adult, male, 19-55 years of age, inclusive, at screening.
• Continuous non-smoker who has not used nicotine containing products for at least 3 months prior to dosing and throughout the study.
• Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
• No clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs
• A non-vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond dosing.
• Must agree not to donate sperm from dosing until 90 days after dosing.
• Be willing and able to comply with the protocol.

You may not qualify if…

• Subject is mentally or legally incapacitated
• History or presence of clinically significant medical or psychiatric condition or disease
• History or presence of alcoholism or drug abuse within the past 2 years prior to dosing.
• History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
• Regularly has less than 1 bowel movement every 2 days.
• Recent history (within 2 weeks of Day 1) of abnormal bowel habits
• Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
• Blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg
• Heart rate is lower than 40 bpm or higher than 99 bpm
• Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to dosing and throughout the study.
• Has been on a diet incompatible with the on study diet
• Donation of blood or significant blood loss within 56 days prior to dosing.
• Plasma donation within 7 days prior to dosing.
• Has received radiolabeled substances or has been exposed to radiation sources over the past 12 months or is likely to receive radiation exposure or radioisotopes within the next 12 months such that participation in this study would increase their total exposure beyond the recommended levels considered safe
• Participation in another clinical study within 28 days prior to dosing.

Where it is running

• Celerion — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.